Detalles de la búsqueda
1.
Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial.
Breast Cancer Res Treat
; 181(1): 61-68, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-32200486
2.
Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer.
Oncologist
; 24(6): 743-e205, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30591548
3.
Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00.
Breast Cancer Res Treat
; 170(2): 351-360, 2018 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-29589138
4.
Impact of body mass index (BMI) on the prognosis of high-risk early breast cancer (EBC) patients treated with adjuvant chemotherapy.
Breast Cancer Res Treat
; 159(1): 79-86, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27460638
5.
Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.
Breast Cancer Res Treat
; 158(2): 323-31, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27372069
6.
Benefit from anthracyclines in relation to biological profiles in early breast cancer.
Breast Cancer Res Treat
; 144(2): 307-18, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24381054
7.
Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial.
Lancet Oncol
; 14(7): 663-70, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23684411
8.
[Radically resected pancreatic cancer and adjuvant treatment. A review of the literature]. / Carcinoma del pancreas resecato radicalmente e terapia adiuvante. Revisione della letteratura.
Recenti Prog Med
; 104(2): 80-5, 2013 Feb.
Artículo
en Italiano
| MEDLINE | ID: mdl-23535964
9.
Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22-00.
Clin Cancer Res
; 29(23): 4908-4919, 2023 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37733800
10.
Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: Final Results From the Phase 2 METEORA-II Randomized Clinical Trial.
JAMA Oncol
; 9(9): 1267-1272, 2023 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37440239
11.
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016).
J Immunother Cancer
; 11(11)2023 11 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38016718
12.
Employment trajectories of young women with breast cancer: an ongoing prospective cohort study in Italy and Switzerland.
J Cancer Surviv
; 17(6): 1847-1858, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35689003
13.
Neoadjuvant Systemic Therapy in Early Breast Cancer: Results of a Prospective Observational Multicenter BRIDE Study.
Cancers (Basel)
; 15(19)2023 Oct 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37835546
14.
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study.
Front Oncol
; 13: 1152123, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37260975
15.
Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study.
Breast Cancer Res Treat
; 134(1): 283-9, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22476856
16.
Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis.
Cancer Discov
; 12(12): 2754-2762, 2022 12 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36255231
17.
Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer.
Breast Cancer Res Treat
; 125(3): 775-84, 2011 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-21132360
18.
Toxic encephalopathy in elderly patients during treatment with capecitabine: literature review and a case report.
J Oncol Pharm Pract
; 17(3): 288-91, 2011 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-20926454
19.
Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer.
Ther Adv Med Oncol
; 13: 1758835920985632, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33613693
20.
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial.
Eur J Cancer
; 153: 133-141, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34153715